caa a22 4500 477072518 CHVBK 20180405111430.0 cr unu---uuuuu 170330e19961101xx s 000 0 eng 10.1007/BF00050990 doi (NATIONALLICENCE)springer-10.1007/BF00050990 Pathologic consequences of increased angiotensin II activity [Elektronische Daten] [Carlos Ferrario, John Flack] Summary: Advances in molecular medicine and pharmacology have allowed clinicians to critically reassess the reninangiotensin system. Angiotensin II (AII) participates in the control of cardiovascular function and electrolyte balance, and plays a part in the regulation of cellular oncogenes and the expression of growth factors. The expression of the proteins of the renin-angiotensin system in organs other than the kidneys suggests that these diverse actions are associated with the peptide in the local environment. Tissue reninangiotensin activity has prompted the investigation of alternate pathways for the production of AII and characterization of novel forms of angiotensin peptides that counteract the vasoconstrictor and proliferative actions of AII. The heptapeptide angiotensin-(1-7) appears to be critically involved in regulating the angiotensinogen activity of AII through stimulation of vasodilator prostaglandins and release of nitric oxide. Study in this area has been accelerated by the identification of receptors that convey the actions of angiotensin peptides at the cellular level and the pharmacologic characterization of agents that inhibit the ability of AII to bind to target receptors. The introduction of a new class of orally active AII-receptor blockers has provided a specific test of the role of AII in the development of essential hypertension and the potential for improved therapy for hypertension and cardiac and vascular sequelae. Kluwer Academic Publishers, 1996 renin-angiotensin system nationallicence angiotensin II nationallicence hypertension nationallicence AT1 receptor nationallicence AT2 receptor nationallicence angiotensin-receptor blocker nationallicence losartan nationallicence Ferrario Carlos Hypertension Center, Bowman Gray/Baptist Hospital Medical Center of Wake Forest University, Winston-Salem, North Carolina aut Flack John Hypertension Center, Bowman Gray/Baptist Hospital Medical Center of Wake Forest University, Winston-Salem, North Carolina aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/5(1996-11-01), 511-518 0920-3206 10:5<511 1996 10 10557 https://doi.org/10.1007/BF00050990 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00050990 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ferrario Carlos Hypertension Center, Bowman Gray/Baptist Hospital Medical Center of Wake Forest University, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Flack John Hypertension Center, Bowman Gray/Baptist Hospital Medical Center of Wake Forest University, Winston-Salem, North Carolina aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/5(1996-11-01), 511-518 0920-3206 10:5<511 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer